A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this study is to evaluate the safety and tolerability of arimoclomol in ALS patients following 90 days of dosing. In addition, the amount of arimoclomol in blood and cerebrospinal fluid will be measured.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CytRx

Criteria

Inclusion Criteria:

• Familial or sporadic ALS

• Vital capacity equal to or more than 60% predicted value for gender, height and age at the screening visit

• First ALS symptoms occurred no more than five years prior to screening

• Must be able to take oral medication

Exclusion Criteria:

• Dependence on mechanical ventilation